Cambridge University to begin COVID-19 vaccine trials; could be 'delivered without needle'

On August 25, University of Cambridge anunced in a press release that it aims to begin clinical trials of its potential COVID-19 vaccine in autumn after UK government’s funding of £1.9 million (US$2.5 million). Cambridge-developed vaccine candidate against SARS-CoV-2  in collaboration with University Hospital Southampton NHS Foundation Trust and a British company DIOSynVax, which, it said, was contributing an ditional £400,000 to trial. Cambridge’s vaccine candidate – DIOS-CoVax2 —has been developed with genetic sequences of “all kwn coronaviruses”, including those from bats, natural hosts of many relatives of human coronaviruses, according to release. 

“Our approach using syntic DNA to deliver custom-designed, immune selected vaccine antigens is revolutionary,” researcher Rebecca Kinsley said. “It is ideal for complex viruses such as coronavirus. If successful, it will result in a vaccine that should be safe for widespre use and that can be manufactured and distributed at low cost,” she ded. 

Re:  COVID-19: Oxford Vaccine Group Chief Hopeful Data Could Go Before Regulators This Year

Re: Patients From Outside, Reopening Of Ecomy Behind Rise In COVID-19 Cases In Delhi: Experts

Lazer specific antigen structures

Cambridge’s unique COVID-19 vaccine candidate has been developed using computer-generated antigen structures infused with syntic genes that train human immune system to target coronavirus. Its response includes include neutralizing antibodies, which block virus infection, and T-cells, which remove virus-infected cells, according to scientists. “This ‘laser-specific’ computer-generated approach is able to help avoid verse hyper-inflammatory immune responses that can be triggered by recognition of wrong parts on coronavirus’s surface,” researchers explained in release. 

Cambridge’s vaccine trials are “different”. Trials will test giving vaccine through people’s skin using a device without needles. It could be a huge breakthrough worldwide to minister cure to a massive number of people—Professor Saul Faust, Director of NIHR Southampton Clinical Research Facility said in press release. 

He of Laboratory of Viral Zootic at University of Cambridge, and founder of DIOSynVax, Professor Jonathan Heeney said, “Our approach involves 3D computer modelling of SARS-CoV-2 virus’s structure. It uses information on virus itself as well as its relatives – SARS, MERS, and or coronaviruses.” While most coronavirus vaccine candidates used RNA or eviruses to deliver antigens, DIOSynVax’s is me out of antigens. UKRI funding will enable human clinical trials of vaccine that is expected to yield breakthrough results. trials will begin at National Institute for Health Research (NIHR) Southampton Clinical Research Facility at University Hospital Southampton NHS Foundation Trust.

Re: COVID-19 Tests Will w Be Required For Nursing Home Staff

Re: Duke And Duchess Of Cambridge Visit rfolk Businesses